Search

Your search keyword '"Abrignani S"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Abrignani S" Remove constraint Author: "Abrignani S" Topic hepacivirus Remove constraint Topic: hepacivirus
40 results on '"Abrignani S"'

Search Results

1. Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.

2. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

3. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

4. Hepatitis C virus-specific directly acting antiviral drugs.

5. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

6. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.

8. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

9. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

10. Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function.

11. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.

12. Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line.

13. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses.

14. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.

15. Prospects for a vaccine against the hepatitis C virus.

16. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells.

17. T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck.

19. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

20. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor.

21. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.

22. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

23. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.

24. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

25. Structure-function analysis of hepatitis C virus envelope-CD81 binding.

26. Prospects for a hepatitis C virus vaccine.

27. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors.

28. Binding of hepatitis C virus to CD81.

29. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties.

30. Perspectives for a hepatitis C virus vaccine.

32. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

34. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.

35. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin: A randomized controlled trial

36. Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs

37. Metabolism of Phosphatidylinositol 4-Kinase IIIα-Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity

38. Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line

39. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

40. Folding and dimerization of Hepatitis C Virus E1 and E2 glycoproteins in stably transfected CHO cells

Catalog

Books, media, physical & digital resources